Most Read Articles
3 days ago
New drug applications approved by US FDA as of 01 - 15 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 

Prior statin use ups survival after cardiac arrest

05 May 2019
Statin side effects are found to be largely related to patients’ negative expectations.

Statins, when taken before cardiac arrest, improve 1-year survival outcomes, a recent study has found.

Accessing the medical records of 142,131 adults with a nontraumatic cardiac arrest, researchers identified those who had (n=4,028; mean age, 69.5±11.8 years; 57.5 percent male) and had not (n=138,103; mean age, 68.1±17.6 years; 63.2 percent male) taken statins 30 days before the cardiac arrest event. The primary clinical outcome was 1-year survival.

Propensity-score matching was performed to reduce selection bias; the resulting groups were comparable in terms of sex, urbanization and most comorbidities. In the matched cohort, those who took statins showed significantly better survival to admission (21.1 percent vs 17.2 percent; p<0.0001) and to hospital discharge (6.1 percent vs 4.3 percent; p<0.0001).

One-year survival was also significantly better in patients who received statins 30 days before the cardiac arrest event (4.8 percent vs 3.2 percent; p<0.0001). This was confirmed by Kaplan-Meier survival analysis, which showed better survival through the 1-year observation period (log-rank p<0.0001).

Logistic regression analysis further identified prior use of statins as an important factor for higher odds of 1-year survival, which remained significant even after adjustments for other independent predictors (odds ratio [OR], 1.41; 95 percent CI, 1.16–1.71; p=0.001).

The significant survival benefit was consistent in patients who used high-potency (rosuvastatin 10 mg; n=1,150; OR, 1.42; 1.04–1.94; p=0.028) and low-potency (atorvastatin 20 mg, including all other statins; n=2,878; OR, 1.43; 1.15–1.79; p=0.002) statins.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
New drug applications approved by US FDA as of 01 - 15 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.